The report "
MediPoint: Biopsy Devices - Global Analysis and Market Forecasts ",
has been prepared based on an in-depth market analysis with inputs
from industry experts.
Cancer
is the uncontrolled growth of abnormal cells in the body. It can
affect numerous organs and tissues of the body. When a patient is
suspected of having a particular type of cancer, a biopsy procedure
is performed to extract a target tissue sample for histological
analysis. This intervention typically provides a definitive cancer
diagnosis for the patient. Given that these procedures play such an
important role in the diagnostic pathway for various cancers, medical
device manufacturers have worked to develop biopsy devices that
maximize the volume and quality of the tissue samples, as well as
decrease their negative impact on the patients body. As seen with
other medical device markets, less invasive biopsy techniques have
entered the market and have established a new gold standard in many
global regions.
View Report at :
http://www.marketresearchreports.biz/analysis/189450
For
this market analysis, the biopsy devices market is segmented by
cancer indication and by the type of biopsy procedure performed.
Beyond providing a general analysis and forecast for each device
segment in different global regions from 20102019, this report offers
a more granular approach by assessing the adoption patterns of the
different biopsy procedure types for specific cancer indications in
specific geographies. This report and forecast focus on the adoption
patterns of surgical biopsies, fine needle aspiration (FNA) devices,
core needle biopsy (CNB) devices, and vacuum-assisted biopsy (VAB)
devices in the diagnosis of breast, prostate, lung, liver, and
thyroid cancers. Additionally, this report and forecast focus on
these adoption patterns in the 10 major global markets, which include
the United States, France, Germany, Italy, Spain, the United Kingdom,
Japan, Brazil, China, and India. This segmentation provides better
business intelligence, so that more effective actions can be taken.
While
the biopsy devices market has matured quite significantly, there are
still significant barriers to overcome and opportunities for growth.
While the US has seen the rapid adoption of VAB devices in the
diagnosis of breast cancer, this market segment will be subjected to
immense pricing pressure during the forecast period covered in this
report. Changes in the reimbursement rates for image-guided breast
biopsy procedures will affect both the average selling prices (ASPs)
of these devices and the adoption levels of alternative
tissue-extraction devices and procedures, including CNBs and open
surgical biopsies. Additionally, the emerging economies will provide
opportunities for growth as access to healthcare improves, adoption
of FNA decreases, and governments work towards implementing cancer
screening programs. This report is intended to elaborate on these
market opportunities and barriers to help current and future
competitors navigate the market.
Download Sample copy of this
Report at : http://www.marketresearchreports.biz/sample/sample/189450
Highlights
Key Questions Answered
- At the start of 2014, the reimbursement scheme for imaged-guided breast biopsy procedures performed in the US underwent significant changes in coding structure and cost levels. (Q). How will this affect the adoption of VAB and CNB devices in the country? (Q). To what extent will the ASPs of VAB devices be affected?
- The biopsy devices markets in the developing economies of the Asia-Pacific (APAC) region and Brazil have higher Compound Annual Growth Rates (CAGRs) than any other country included in this report. (Q). Which countries will have the highest CAGRs in the FNA market, the CNB market, and the VAB market?
- The major players in the VAB and CNB markets are drastically different. (Q). What is the global company share in the VAB and CNB markets? (Q). How will their market share shift through 2019?
- New technologies, such as liquid and optical biopsies, are being developed as less invasive techniques to obtain a cancer diagnosis. (Q). What is the likelihood that these technologies could replace the conventional biopsy devices? (Q). Which companies are the furthest along in the development of these technologies?
- The benefits of mass screening programs on prostate cancer mortality are controversial. (Q). What are the results of the major randomized clinical trials assessing a prostate cancer screening programs effectiveness? (Q). How will this impact the institution of a mass prostate cancer screening program in the countries covered in this report?
Reasons to buy
- What Do Physicians Think? quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. This information is essential for all strategic decision-makers in every organization, allowing them to act on high-quality information.
Browse
Latest News at http://www.marketresearchreports.biz/articles
Table of Contents
1
Table of Contents
1
Table of Contents 6
1.1
List of Tables 10
1.2
List of Figures 13
2
Introduction 15
2.1
Overview 15
2.2
Catalyst 16
2.3
Related Reports 16
3
Industry Overview 17
3.1
Types of Biopsies 17
3.1.1
Surgical Biopsy 17
3.1.2
Fine Needle Aspiration 17
3.1.3
Core Needle Biopsy 18
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment